Table 2.
Patient demographics by treatment group
| Peptide | Arm A | Arm B | Arm C | Total | |
| pBCAR3 | pIRS2 | Both | |||
| N | 3 | 3 | 9 | 15 | |
| Gender (female) | 1 | 1 | 4 | 6 (40%) | |
| Caucasian, non-Hispanic | 2 | 3 | 9 | 11 (92%) | |
| Hispanic | 1 | 0 | 0 | 1 (7%) | |
| Age—median (range) | 64 (40–67) | 63 (50–85) | 52 (30–75) | 56 (30–85) | |
| Performance status 0 | 2 | 3 | 8 | 13 (87%) | |
| Stage at registration | II–IIIA | 0 | 0 | 4 | 4 (27%) |
| IIIB, IIIC | 1 | 1 | 5 | 7 (47%) | |
| IV | 2 | 2 | 0 | 4 (27%) | |
| Distant metastatic sites | None | 1 | 1 | 9 | 11 |
| Nodes | 1 | 0 | 0 | 1 | |
| Soft tissue | 0 | 2 | 0 | 2 | |
| Lung | 0 | 1 | 0 | 1 | |
| Brain | 1 | 0 | 0 | 1 | |
| Other visceral | 0 | 1 | 0 | 1 | |
| Clinically NED at study entry | 3 | 3 | 9 | 15 (100%) | |
NED, no evidence of disease; pBCAR3, phosphopeptide from breast cancer antiestrogen resistance 3; pIRS2, phosphopeptide from insulin receptor substrate 2.